Advertisement
Advertisement
MLTX
MoonLake Immunotherapeutics Class A Ordinary Shares
11.53
USDSponsored
+0.73
+6.76%
Nov 06, 15:59 UTC -5
Closed
After-Market
12.12
+0.59
+5.15%
MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Earnings
MLTX Earnings Reports
Positive Surprise Ratio
MLTX beat 10 of 17 last estimates.
59%
Next Report
Date of Next Report
Nov 17, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.79
Implied change from Q2 26 (Revenue/ EPS)
--
/-5.95%
Implied change from Q3 25 (Revenue/ EPS)
--
/-28.18%
MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue
On Aug 10, 2026, MLTX reported earnings of -0.84 USD per share (EPS) for Q2 26, beating the estimate of -0.93 USD, resulting in a 10.35% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.73% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -0.79 USD, with revenue projected to reach -- USD, implying an decrease of -5.95% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$0.84, beating estimates by 10.35%, and revenue of $0.00, 0% as expectations.
How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved up 2.73%, changed from $17.55 before the earnings release to $18.03 the day after.
When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 17, 2026.
What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?
Based on 11
analysts, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$0.79 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.